Affymax, Inc.

Kai Pharmaceuticals, Inc.

Amgen Inc.

Sutro Biopharma, Inc.

Glaxo Group Limited

Glaxo Wellcome Inc.

Qun Yin

Derek Maclean

Peter J Schatz

Christopher P Holmes

David Tumelty

Genet Zemede

Felix D Karim

Guy Lalonde

Amos Baruch

Kanad Das

William J Dower

Ronald W Barrett

Steven E Cwirla

Palani Balu

Christian M Gates

Christopher R Wagstrom

Richard Wayne Hendren

Palaniappan Balasubramanian

Surekha Podduturi

Balu Palani

Randolph B DePrince

Wenjin Yang

Toni Beth Kline

Krishna Bajjuri

Bruce England

Felix Karim

Randoph B DePrince

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Stable liquid formulation of AMG 416 (etelcalcetide)

Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W, W, W, SG, and R are as described herein.

Hemiasterlin derivatives for conjugation and therapy

Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis. 

Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X-X-X-X-X-X-X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Therapeutic agents for reducing parathyroid hormone levels

Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Peptides that bind to the erythropoietin receptor

The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure:&#x2014;NH&#x2014;(CH)&#x2014;[O&#x2014;(CH)]&#x2014;O&#x2014;(CH)&#x2014;Y&#x2014;wherein &#x3b1;, &#x3b2;, &#x3b3;, &#x3b4;, and &#x3b5; are each integers whose values are independently selected.

Spacer moiety for poly(ethylene glycol) modified peptide based compounds

Growing community of inventors

Palo Alto, CA, United States of America

Qun Yin